Rabelock, lyophilizate 20 mg

Rabelok is an antiulcer drug, an inhibitor of H+-K+-ATPase (proton pump).

The mechanism of action is associated with inhibition of the enzyme H+-K+-ATPase in the parietal cells of the stomach, which leads to blocking the final stage of hydrochloric acid formation.

This action is dose-dependent and results in inhibition of both basal and stimulated hydrochloric acid secretion regardless of the nature of the stimulus.

Indications

Active ingredient

Composition

Active ingredient:

Rabeprazole sodium 20 mg;

Associates:

Mannitol 75 mg,

Sodium hydroxide to pH 11.0.

How to take, the dosage

It is taken orally. A single dose is 10-20 mg. Frequency and duration of use depend on the indication and the treatment regimen.

Interaction

Concomitant use with digoxin may increase (mild to moderate) plasma concentrations of digoxin.

Concomitant use with ketoconazole decreases its bioavailability.

Special Instructions

Before starting therapy, malignant neoplasms of the stomach should be excluded, since the use of rabeprazole may mask symptoms and delay correct diagnosis.

Patients with hepatic or renal impairment do not require dose adjustment, but in patients with severe hepatic impairment rabeprazole is recommended with caution.

In concomitant use with rabeprazole, the doses of ketoconazole and digoxin should be adjusted.

In experimental studies no carcinogenic effect of rabeprazole was established, however, in the study of mutagenicity there were mixed results. Tests on lymphoma cells in mice were positive, while the in vivo micronucleus test and the in vivo and in vitro DNA repair test were negative.

Contraindications

Pregnancy, lactation (breastfeeding), hypersensitivity to rabeprazole sodium or substituted benzimidazoles.

Side effects

The digestive system: diarrhea, nausea, abdominal pain, vomiting, flatulence, constipation; rarely – dry mouth, dyspepsia, belching; in single cases – anorexia, gastritis, stomatitis, increased activity of liver transaminases.

CNS and peripheral nervous system disorders: headache, asthenia, dizziness, insomnia; rarely – nervousness, somnolence; in single cases – depression, visual and taste disorders.

Respiratory system: possible – rhinitis, pharyngitis, cough; rarely – sinusitis, bronchitis.

Allergic reactions: rare – skin rash; in isolated cases – itching.

Others: back pain, flu-like syndrome; rarely – myalgia, chest pain, chills, cramps of the calf muscles, urinary tract infection, arthralgia, fever; in single cases – weight gain, increased sweating, leukocytosis.

Pregnancy use

Rabeprazole is contraindicated in pregnancy and lactation.

In experimental studies it has been established that rabeprazole crosses the placental barrier in small amounts, but no impairment of fertility or defects of fetal development have been noted; it is excreted with milk of lactating rats.

There is no clinical experience with rabeprazole in children, so its use is not recommended.

Similarities